Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity
Although circulating tumour DNA (ctDNA) can predict immune checkpoint blockade (ICB) responses, its association with tumour biomarkers remains unknown. Here, the authors use ctDNA to inform exome and transcriptome profiling of >100 patients with 30 cancer types on a single clinical ICB trial and...
Guardado en:
Autores principales: | S. Y. Cindy Yang, Scott C. Lien, Ben X. Wang, Derek L. Clouthier, Youstina Hanna, Iulia Cirlan, Kelsey Zhu, Jeffrey P. Bruce, Samah El Ghamrasni, Marco A. J. Iafolla, Marc Oliva, Aaron R. Hansen, Anna Spreafico, Philippe L. Bedard, Stephanie Lheureux, Albiruni Razak, Vanessa Speers, Hal K. Berman, Alexey Aleshin, Benjamin Haibe-Kains, David G. Brooks, Tracy L. McGaha, Marcus O. Butler, Scott V. Bratman, Pamela S. Ohashi, Lillian L. Siu, Trevor J. Pugh |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2a55653c8f4a4ed888f461e4bdb5696f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy.
por: Morven Cunningham, et al.
Publicado: (2021) -
Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma
por: S. C. Sasson, et al.
Publicado: (2021) -
Hypertrophic lichenoid dermatitis during pembrolizumab treatment
por: Ryoma Honda, et al.
Publicado: (2021) -
A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma
por: Wu L, et al.
Publicado: (2021) -
Durable Response with Single-Agent Pembrolizumab in a Patient with Metastatic Melanoma
por: Sanju Cyriac, et al.
Publicado: (2021)